Summary

This article presents data from A Safety and Efficacy Study of Oral MDV 3100 [enzalutamide] in Chemotherapy-Naïve Patients With Progressive Metastatic Prostate Cancer [PREVAIL; NCT01212991; Beer TM et al. N Engl J Med 2014]. Enzalutamide, an androgen receptor inhibitor, has been shown to improve overall survival (OS) and radiographic progression-free survival (rPFS) in men with metastatic castrate-resistant prostate cancer (mCRPC) who had received docetaxel therapy [Scher H et al. N Engl J Med 2012]. PREVAIL researchers examined whether enzalutamide could prolong OS and rPFS in men with mCRPC who had progressed on androgen deprivation therapy.